Ritlecitinib

Ritlecitinib is an orally available small molecule inhibitor of Janus kinase 3 (JAK3) that is used to treat severe alopecia areata. Ritlecitinib is associated with a low rate of transient and usually mild elevations in serum aminotransferase levels during therapy but has yet to be linked to cases of clinically apparent acute liver injury. It is grouped under the following drug class(es): Immunosuppressants and JAK inhibitors. Its therapeutic use is listed as anti-inflammatories and dermatologicals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include ritlecitinibum, Litfulo and PF06651600. Its PubChem CID is 118115473.

CAS No 1792180-81-4
Molecular Formula C15H19N5O
Molecular Weight 285.34 g/mol
Synonyms 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one

Frequently Asked Questions